Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2020
FDA approves ViiV Healthcare's Rukobia
The US Food and Drug Administration approved ViiV Healthcare's Rukobia (fostemsavir) for use with other antiretroviral therapies in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
2020
FDA approves pediatric Tivicay PD tablet
The FDA approved ViiV Healthcare’s Tivicay PD dispersible tablet, in combination with other antiretrovirals, for HIV treatment in children at least 4 weeks old who weigh at least 6 pounds 10 ounces.
2020
ViiV Healthcare establishes £3 million COVID-19 response fund
ViiV Healthcare established a £3 million fund to support research into COVID-19's medical and scientific impact on people living with HIV and community-based activities addressing challenges they face. The fund was divided equally between research and community response programmes, each receiving up to £1.5 million.
2019
ViiV Healthcare announces exclusive N6LS licensing agreement with NIAID
ViiV Healthcare announced that it will develop investigational antibody N6LS for HIV treatment and prevention under an exclusive licensing agreement between GSK and NIAID, part of the National Institutes of Health. The announcement describes development plans, not a completed treatment launch.